Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katarina Luptakova

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Immune therapy in multiple myelomaKatarina Luptakova, David Avigan
The American Journal of Case Reports|September 4, 2014
A 78-year-old man with acute myeloid leukemia (AML) and acute renal failureElliot B Tapper, Katarina Luptakova, Robin M Joyce, et al.
Case Reports in Hematology|November 29, 2014
Primary cardiac burkitt lymphoma presenting with abdominal painDimitrios Tzachanis, Rajan Dewar, Katarina Luptakova, et al.
Advances in Hematology|March 7, 2019
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in FranceHuamao Mark Lin, Keith L Davis, James A Kaye, et al.
Journal of Geriatric Oncology|October 24, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapiesParameswaran Hari, Dorothy Romanus, Katarina Luptakova, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 6, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosisParameswaran Hari, Huamao Mark Lin, Carl V Asche, et al.
Blood|February 18, 2010
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cellsBritta Will, Tanya Siddiqi, Meritxell Alberich Jordà, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2018
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesParameswaran Hari, Dorothy Romanus, Antonio Palumbo, et al.
Acta Haematologica|February 14, 2015
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplantJon E Arnason, Katarina Luptakova, Jacalyn Rosenblatt, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
Immune therapy in multiple myelomaKatarina Luptakova, David Avigan
The American Journal of Case Reports|September 4, 2014
A 78-year-old man with acute myeloid leukemia (AML) and acute renal failureElliot B Tapper, Katarina Luptakova, Robin M Joyce, et al.
Case Reports in Hematology|November 29, 2014
Primary cardiac burkitt lymphoma presenting with abdominal painDimitrios Tzachanis, Rajan Dewar, Katarina Luptakova, et al.
Advances in Hematology|March 7, 2019
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in FranceHuamao Mark Lin, Keith L Davis, James A Kaye, et al.
Journal of Geriatric Oncology|October 24, 2017
The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed/refractory multiple myeloma in the era of novel therapiesParameswaran Hari, Dorothy Romanus, Katarina Luptakova, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|January 6, 2018
Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosisParameswaran Hari, Huamao Mark Lin, Carl V Asche, et al.
Blood|February 18, 2010
Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cellsBritta Will, Tanya Siddiqi, Meritxell Alberich Jordà, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 4, 2018
Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed/Refractory Multiple Myeloma in Routine Clinical Care in the United StatesParameswaran Hari, Dorothy Romanus, Antonio Palumbo, et al.
Acta Haematologica|February 14, 2015
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplantJon E Arnason, Katarina Luptakova, Jacalyn Rosenblatt, et al.
Blood Cancer Journal|November 11, 2018
Interpreting clinical trial data in multiple myeloma: translating findings to the real-world settingPaul G Richardson, Jesus F San Miguel, Philippe Moreau, et al.
Pageof 2